Glaukos Q1 net sales record $106.7M (+25% YoY); net loss narrows to $0.32/sh from $0.82

GLAUKOS Corp

2025-Q1 EPS reported -$0.32 revenue$106,664,000

Record Q1 net sales $106.7M, up 25% reported and 26% constant currency vs $85.6M last year.
U.S. Glaucoma sales $59.1M (+41% YoY); total Glaucoma $88.1M (+31% YoY).
GAAP net loss $18.1M ($0.32/sh) vs $40.8M ($0.82/sh) in Q1 2024; non-GAAP net loss $12.6M ($0.22).
Gross margin ~77%; non-GAAP gross margin ~82%; operating loss improved to $20.7M from $39.1M.
Reaffirmed FY 2025 net sales guidance of $475M-$485M; cash $303.4M with no debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.